Yazar "Menekse, Serkan" için listeleme
-
The mean platelet volume may predict the development of isolated bone metastases in patients with breast cancer: a retrospective study of the Young Researchers Committee of the Turkish Oncology Group (TOG)
Tanrıverdi, Özgür; Menekse, Serkan; Teker, Fatih; Oktay, Esin; Pilanci, Kezban Nur; Gunaldi, Meral; Yanmaz, Mustafa Teoman (Zerbinis Medical Publ, 2016)Purpose: To determine the predictive value of the mean platelet volume (MPV) and the MPV/platelet count ratio on the development of isolated bone metastasis in patients with breast cancer. Methods: A total of 121 previously ... -
Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group
Tanrıverdi, Özgür; Cokmert, Suna; Oktay, Esin; Pilanci, Kezban Nur; Menekse, Serkan; Kocar, Muharrem; Meydan, Nezih (Humana Press Inc, 2014)Non-small cell lung cancer (NSCLC) is one of the most common cancers. Most of the patients are inoperable at the time of diagnosis, and the prognosis is poor. Many prognostic factors have been identified in prior studies. ... -
A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)
Degirmencioglu, Serkan; Tanrıverdi, Özgür; Menekse, Serkan; Dogan, Mutlu; Hacioglu, Bekir; Oktay, Esin; Nayir, Erdinc (Imprimatur Publications, 2019)Purpose: To compare the efficacy and adverse effect profiles of the first-line treatment of patients with KRAS wild type metastatic colorectal cancer (CRC) in Turkey who were treated based on regimens including bevacizumab, ... -
XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology
Duran, Ayse Ocak; Karaca, Halit; Besiroglu, Mehmet; Bayoglu, Ibrahim Vedat; Menekse, Serkan; Yapici, Heves Surmeli; Ozkan, Metin (Asian Pacific Organization Cancer Prevention, 2014)Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this study was to compare ...
